Atlas FDA

PEN

11 FDA 510(k) clearances · Product code

90 daysmedian time to decision
203 days90th percentile
11clearances measured

FDA profile

Official device name
Gram-Negative Bacteria And Associated Resistance Markers
Device class
Class II (moderate risk)
Regulation
21 CFR 866.3365
Medical specialty
Microbiology
FDA definition
A qualitative multiplexed in vitro diagnostic device to detect and identify gram-negative bacteria and resistance markers in positive blood cultures.
Adverse events (MAUDE)
2021: 15
Reports received by FDA, not confirmed device causation - volume tracks device popularity as much as risk.
Sort:Newest firstOldest first

Export predicate table (CSV) Shareable report ◉ Watch exports: 3 free/month · reports & watching: free

RecordFirmDate
LIAISON PLEX Gram-Negative Blood Culture Assay (K243013)Luminex Corporation2025-04-18
BIOFIRE Blood Culture Identification 2 (BCID2) Panel (RFIT-ASY-0147 (30 pack) RFIT-ASY-0148 (6 pack)) (K243759)Biofire Diagnostics, LLC2024-12-20
ePlex Blood Culture Identification Gram Negative (BCID-GN) Panel (K213236)Genmark Diagnostics, Incorporated2022-04-27
BioFire Blood Culture Identification 2 (BCID2) Panel (K193519)Biofire Diagnostics, LLC2020-03-18
iC-GN iC-Cassette for use on the iC-System (K190341)Icubate, Inc.2019-06-28
ePlex Blood Culture Identification Gram Negative (BCID-GN) Panel (K182619)Genmark Diagnostics, Incorporated2019-04-12
FilmArray Blood Culture Identification (BCID) Panel (K181493)Biofire Diagnostics, LLC2018-07-05
FilmArray Blood Culture Identification (BCID) panel for use with FilmArray Torch (K160457)Biofire Diagnostics, LLC2016-03-15
FilmArray Blood Culture Identification (BCID) Panel for use with the FilmArray 2.0 (K143171)Biofire Diagnostics, LLC2015-01-30
VERIGENE GRAM NEGATIVE BLOOD CULTURE NUCLEIC ACID TEST (BC-GN) (K132843)Nanosphere, Inc.2014-01-08
FILMARRAY BLOOD CULTURE IDENTIFICATION (BCID) PANEL (K130914)Biofire Diagnostics, Inc.2013-06-21

Track PEN automatically

Every clearance here is in the API, with alerts when new ones post.